Contact this trialFirst, we need to learn more about you.
Checkpoint Inhibitor
Immunotherapy for Renal Medullary Carcinoma
Recruiting2 awardsPhase 2
Houston, Texas
This trial is testing if a combination of two drugs, nivolumab and relatlimab, can help control a type of kidney cancer called renal medullary carcinoma that has spread or is hard to treat. These drugs work by helping the immune system recognize and attack cancer cells. The goal is to improve treatment outcomes. Nivolumab has been approved for the treatment of various cancers, including renal cell carcinoma, and is often used in combination therapies.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service